Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 1/20 | 0.33 |
| ▸ | HTR2C | P28335 | 1/20 | 0.33 |
| ▸ | HTR2B | P41595 | 1/20 | 0.33 |
| ▸ | MTNR1A | P48039 | 5/20 | 0.33 |
| ▸ | MTNR1B | P49286 | 5/20 | 0.33 |
| ▸ | OGA | O60502 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12169539 | 0.89 | HTR2C (0.36) | HTR2AHTR2CHTR2B | |
| SCHEMBL13054417 | 0.81 | FABP4 (0.39) | HTR2AHTR2CHTR2BMTNR1AMTNR1B | |
| SCHEMBL3600857 | 0.76 | UGT2B17 (0.36) | HTR2B | |
| SCHEMBL20993841 | 0.74 | PARP1 (0.33) | — | |
| SCHEMBL23012562 | 0.73 | MAPT (0.35) | — | |
| SCHEMBL23729378 | 0.73 | ALDH1A1 (0.34) | HTR2B | |
| SCHEMBL5535613 | 0.73 | SELL (0.39) | — | |
| SCHEMBL23647751 | 0.73 | ALDH1A1 (0.31) | — | |
| SCHEMBL5535609 | 0.73 | MAOB (0.33) | — | |
| SCHEMBL9910076 | 0.72 | HTR2C (0.39) | HTR2AHTR2CHTR2BMTNR1AMTNR1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11912668-B2 | GCN2 and perk kinase inhibitors and methods of use thereof | DECIPHERA PHARMACEUTICALS, LLC (US) | 2024-02-27 | — | — | US | disclosed |
| US-10968213-B2 | Cyclopropanamine compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2021-04-06 | — | — | US | disclosed |
| US-20190315735-A1 | CYCLOPROPANAMINE COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICALS CO (JP) | 2019-10-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190315735-A1 | CYCLOPROPANAMINE COMPOUND AND USE THEREOF | KDM1A, KDM1B, KDM2A | HTR2A 2060/4885HTR2C 3062/4885HTR2B 2883/4885 |
| US-10968213-B2 | Cyclopropanamine compound and use thereof | KDM1A, KDM1B, KDM2A | HTR2A 2060/4885HTR2C 3062/4885HTR2B 2883/4885 |
| US-11912668-B2 | GCN2 and perk kinase inhibitors and methods of use thereof | EIF2AK4, GCN1, MAPKAPK2 | HTR2A 3263/4885HTR2C 3099/4885HTR2B 2683/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.